Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Vera Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "VERA THERAPEUTICS, INC. Condensed Statements of Operations and Comprehensive Loss Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 16,231 $ 10,112 $ 41,340 $ 22,661 General and administrative 5,739 4,945 11,887 9,417 Total operating expenses 21,970 15,057 53,227 32,078 Loss from operations Total other income, net 1,808 204 2,996 140 Net loss $ $ $ $ Other comprehensive gain 82 Comprehensive loss $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 44,269,772 27,078,450 40,986,907 25,660,742 VERA THERAPEUTICS, INC. Condensed Balance Sheets June 30, December 31, 2023..."
05/11/2023 8-K Quarterly results
Docs: "VERA THERAPEUTICS, INC. Condensed Statements of Operations and Comprehensive Loss Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 25,108 $ 12,549 General and administrative 6,150 4,472 Total operating expenses 31,258 17,021 Loss from operations Total other income , net 1,189 Net loss $ $ Other comprehensive gain $ 220 $ Comprehensive loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 37,667,566 24,227,282 VERA THERAPEUTICS, INC. Condensed Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and short-term marketable securities $ 197,153 $ 114,653 Prepaid expense..."
03/28/2023 8-K Quarterly results
03/10/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/02/2023 8-K Quarterly results
02/01/2023 8-K Quarterly results
01/30/2023 8-K Investor presentation
Docs: "Slide presentation entitled “Origin Phase 2b Clinical Trial Data Update”"
01/03/2023 8-K Investor presentation
Docs: "Slide presentation entitled “Origin Phase 2b Clinical Trial Week 24 Results”"
11/09/2022 8-K Quarterly results
Docs: "VERA THERAPEUTICS, INC. Condensed Statements of Operations and Comprehensive Loss Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating expenses: Research and development $ 19,656 $ 3,564 $ 42,317 $ 9,731 General and administrative 5,588 3,688 15,005 8,086 Total operating expenses 25,244 7,252 57,322 17,817 Loss from operations Total other income , net 565 705 2,055 Net loss $ $ $ $ Unrealized loss on available-for-sale securities - - Total loss and comprehensive loss $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 27,215,874 21,265,519 26,184,816 10,793,436 VERA THERAPEUTICS, INC. Condensed..."
09/09/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
04/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/24/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results • Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 • Acquired MAU868, a first-in-class monoclonal antibody to treat BK Virus infections, full results from interim analysis of Phase 2 study of MAU868 in kidney transplant recipients planned for mid-2022 • Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis planned for 2H-2022 • BK Virus and MAU868 key opinion leader webinar to be held Tuesday, March 29, 2022 • Management to host business update webcast today at 8:00 a.m. ET"
12/17/2021 8-K Quarterly results
12/15/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "VERA THERAPEUTICS, INC. Unaudited Condensed Statements of Operations and Comprehensive Loss Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Operating expenses: Research and development $ 3,564 $ 1,969 $ 9,731 $ 5,362 General and administrative 3,688 652 8,086 2,903 Restructuring Costs - 1,416 - 1,416 Total operating expenses 7,252 4,037 17,817 9,681 Loss from operations Total other income , net 2,055 Net loss and comprehensive loss $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 21,265,519 325,985 10,793,436 322,811 VERA THERAPEUTICS, INC. Unaudited Balance Sheets September 30, December 31, 2021..."
08/16/2021 8-K Quarterly results
07/14/2021 8-K Quarterly results
06/24/2021 8-K Quarterly results
05/18/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy